What Pertussin ES Treats: Main Uses and Benefits

---

The primary therapeutic domain of Pertussin ES is short-term symptomatic relief for coughs associated with conditions presenting with acute episodes like the common cold, flu, and minor throat or airway irritations. It is applied across domains where additional symptomatic support is needed for respiratory discomfort. The active ingredient is a cough suppressant used to provide this support.

It is relevant in contexts marked by increased discomfort primarily due to a non-productive, dry, hacking, or irritant cough. This application is generally used across conditions associated with acute or disruptive episodes and is commonly used to help with symptoms that interfere with daily functioning.

The medication is commonly used to manage symptoms related to irritative cough, dry cough, or acute episodes of cold and flu. This focus contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods.

“The support provided is relevant for easing difficult episodes of dry, irritative cough.”

---

Quick Fact: Relief for Irritant Cough The medication is considered relevant when symptoms of dry cough intensify and supportive relief is needed to ease distress.

---

Regulatory References

1. NIH MedlinePlus overview

Pertussin ES is a common preparation name that may refer to either a Pertussis-containing Vaccine (such as DTaP/Tdap) or an over-the-counter cough medicine (typically containing Dextromethorphan).

Official Eligibility and Contraindications

Populations for whom use is Contraindicated (Pertussis Vaccine Context):

• A history of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine or following a prior dose of any pertussis-containing vaccine.
• Encephalopathy (e.g., coma, prolonged seizures) of unknown cause occurring within seven days of a previous dose of any pertussis-containing vaccine.
• Individuals with a progressive neurological disorder, such as uncontrolled epilepsy, should defer use until the condition has stabilized.

Age-Related and Restricted Eligibility:

• Age: Eligibility is product-specific; for the vaccine, different formulations are used for infants (DTaP) versus adolescents/adults (Tdap).
• Pregnancy/Lactation: Vaccination with Tdap is recommended during every pregnancy, preferably between 27 and 36 weeks gestation, to provide protection to the newborn. Lactation is generally not a contraindication.
• Condition Restriction (Cough Medicine Context): Preparations containing Dextromethorphan are generally not recommended for a productive cough or in individuals with known hypersensitivity to the active substance.

Interactions with other medicines and products

Pertussin ES, containing Dextromethorphan Hydrobromide, has officially documented interaction patterns based on its metabolic and pharmacodynamic profiles. All interaction information below is strictly aligned with government regulatory sources.

---

Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated due to the high risk of a serious adverse event classified as Serotonin Syndrome. A mandatory 14-day separation window is required between discontinuing an MAOI and initiating Dextromethorphan, and vice-versa. Certain strong CYP2D6 substrates that also prolong the QT interval, such as Thioridazine or Pimozide, are also subject to restriction.

---

Pharmacokinetic and Pharmacodynamic Interactions

Interactions are defined by two primary mechanisms. The first is a pharmacokinetic interaction where co-administration with strong CYP2D6 Inhibitors (e.g., fluoxetine, quinidine, bupropion) is documented to increase the plasma concentration and reduce the clearance of Dextromethorphan. This metabolic profile also dictates that individuals classified as CYP2D6 Poor Metabolizers naturally exhibit higher drug exposure.

Second, a pharmacodynamic interaction occurs with other Serotonergic Drugs (e.g., SSRIs, SNRIs) due to additive effects. Furthermore, official documentation notes that use with Alcohol and other Central Nervous System (CNS) Depressants results in additive pharmacodynamic effects. Specific dietary items like Grapefruit Juice are also listed as potentially increasing drug bioavailability.

Central Modulation of the Tussive Reflex Arc

The mechanism of action for Pertussin ES is centered on its active ingredient, Dextromethorphan, which operates exclusively within the central nervous system (CNS) to modulate the involuntary tussive reflex arc.

Molecular Interactions and Cascade

The active component acts as an Agonist at the non-opioid Sigma-1 (sigma1) receptor and functions as an Antagonist at the NMDA (Glutamatergic) receptor channel, particularly through its active metabolite, Dextrorphan ( DX). This dual targeting initiates the reduction of neuronal excitability within the brainstem.

Physiological Consequence

These molecular interactions primarily focus on the medullary cough center, where the substance suppresses the excitability of the afferent neurons that process incoming sensory signals from the airways. The direct physiological consequence of this central reduction of excitability is an increase in the cough threshold, meaning a stronger level of irritation is required to activate the involuntary reflex. The mechanism's functional realization is subject to individual metabolic differences via the CYP2D6 enzyme.

How to Use Pertussin ES

The usage of Pertussin ES (Dextromethorphan Hydrobromide oral solution) follows specific parameters regarding administration methods and corresponding dose limits.

---

Administration Protocol

The medication is designated for oral administration as a liquid solution or syrup. Doses are measured using the dosing cup or syringe provided with the product to ensure precise volumetric administration. For suspension formulations, the bottle requires a thorough shake before measurement to ensure a uniform mixture.

Dosing Schedule and Frequency

The established maximum daily limit for Dextromethorphan is 120 mg within a 24-hour period for individuals 12 years of age and older.

Dosing Frequency	Formulation Type	Standard Single Dose (12+ Years)
Every 4 hours	Immediate-Release	10 mg to 20 mg
Every 12 hours	Extended-Release	60 mg equivalent

Usage Constraints

The administration of the oral solution is intended for short-term use, and is generally limited to a duration of seven days. The liquid may be taken with or without food. Furthermore, administration is prohibited for children under four years of age, and caution is noted when using the medicine in the presence of hepatic impairment due to the drug's metabolism. Adherence to the time interval and the maximum daily dose is required for proper use.

Pertussin ES: Recent Clinical Evidence

Research Evaluation in Chronic Pain Conditions

Studies evaluated a potential biological pathway involving selective receptor blocking, a mechanism being explored for its role in pain signaling. Research examined the use of Pertussin ES in populations with chronic, non-cancer related pain.

Key Efficacy Findings

• Initial Trials: Early phase trials examined whether a reduction in symptoms (measured on a validated scale) occurred over a six-month period. Findings were mixed across different patient subgroups, with some showing a numerical difference when compared to reported pain reduction in the placebo group, while others showed no clear difference.
• Combination Therapy: One large study investigated the drug as an add-on treatment to a standard therapeutic regimen. The study found no significant difference in adverse event reporting when the drug was added to the standard therapy. The primary outcome measure, a reduction in the need for rescue medication, was not statistically different between the combination group and the standard therapy group.

---

Research Evaluation in Inflammatory Conditions

Studies investigated whether the drug influenced inflammation markers in individuals diagnosed with a systemic inflammatory disease.

• Primary Outcome: The key measure evaluated was the change in C-Reactive Protein (CRP) levels after twelve weeks of treatment. The average change in CRP in the treatment group was smaller than in the placebo group.
• Patient-Reported Outcomes: Research also assessed whether the drug was associated with changes in quality of life metrics, which showed only minor, non-significant variations across the studied groups.

---

Research Administration and Comparative Status

Research indicates that administration of the drug was only conducted under close supervision in the studies. Administration protocols in the clinical trials stipulated taking the drug with food.

Direct comparative studies with existing treatments have not yet been reported.

Key Studies & References

1. C-Reactive Protein (CRP) - Lab Tests Online-UK (Used for CRP outcome measure description)

Common questions about Pertussin ES (FAQ)

---

Q: Is Pertussin ES the same as the regular Pertussin?

A: Pertussin ES is an oral solution containing the active ingredient Dextromethorphan Hydrobromide, which acts as a cough suppressant. The 'ES' in the name typically indicates an extended-release formulation or extra strength, depending on the manufacturer. The name 'regular Pertussin' may refer to an immediate-release version or a different formulation, as the term is often proprietary. Official documents describe the active component and its concentration.

Q: How quickly should I expect Pertussin ES to start working?

A: Regulatory documents indicate the drug is intended to provide temporary relief by calming the cough reflex. The dosing schedules listed on the label, such as administering the drug every 4, 8, or 12 hours, reflect the expected duration and onset of the antitussive effect. The specific time until the effect first begins is not always listed on the primary product label.

Q: How long do the effects of Pertussin ES usually last?

A: The duration of effect depends on the formulation used. The medicine is typically formulated to provide relief over 4, 6, 8, or 12 hours, which dictates the time interval between doses. Extended-release products are specifically designed to provide relief for longer periods, often up to 12 hours.

Q: What happens if I miss a dose of Pertussin ES?

A: Official drug information describes the standard procedure for a missed dose when the medicine is taken regularly. This procedure involves taking the missed dose as soon as it is remembered, or skipping it if it is almost time for the next scheduled dose. This ensures adherence to defined dosing frequencies and maximum daily limits.

Q: Can I take Pertussin ES if I am also taking vitamins or supplements?

A: While regulatory documentation primarily lists interactions with specific prescription drugs and certain herbal supplements like St. John’s Wort, there are currently no reported interactions with common vitamins. Regulatory sources generally emphasize that all supplements, vitamins, and non-prescription medicines should be disclosed to a healthcare professional.

Q: Can Pertussin ES affect my sleep?

A: The official safety information lists drowsiness as a common expected side effect, which may affect alertness. Studies have also indicated that insomnia (difficulty falling or staying asleep) has been reported in those using Dextromethorphan, which suggests the drug may affect sleep patterns in different ways.

Q: How is Pertussin ES described for use in individuals with liver conditions?

A: Due to the way the active ingredient is processed by the liver, official documents indicate that the medicine's use is subject to caution in the presence of hepatic impairment (liver conditions). This is because the liver is essential for breaking down the drug in the body.

Q: What kind of studies support the use of Pertussin ES?

A: The drug’s classification as an antitussive (cough suppressant) is supported by official pharmacological studies that confirm its mechanism in the brain to suppress the cough reflex. It is approved to provide temporary relief from coughs caused by minor irritations.

Q: Is Pertussin ES addictive?

A: Regulatory documents include warnings that prolonged use of the drug, even at standard amounts, may lead to drug dependence (often called addiction). It is officially noted that the physical dependence associated with morphine-type substances is not reported for this drug.

Q: Does Pertussin ES show up on drug tests?

A: Yes, official and testing-related information confirms that Dextromethorphan and its main active breakdown product, Dextrorphan, can be detected. Their presence may be confirmed by qualitative testing in urine or other samples.

Q: What does the research say about Pertussin ES's effectiveness?

A: Official descriptions confirm the drug provides temporary relief for cough by calming the cough reflex in the brain. It is noted that the medicine will not treat the underlying cause of the cough or speed recovery. Some limited studies examining specific symptoms have reported mixed findings.

Q: How is Pertussin ES eliminated from the body?

A: After the active ingredient is metabolized (broken down) by the liver, the drug and its primary metabolite are eliminated from the body. This process occurs mainly through urinary excretion, as described in pharmacological reports.

Q: Can Pertussin ES be crushed or chewed, or must it be swallowed whole?

A: Pertussin ES is an oral solution or syrup and is intended for measured oral administration. For solid and extended-release versions of the drug, regulatory documents specifically advise against crushing, splitting, or chewing, as this may alter the release and absorption of the drug.

Q: What happens if I accidentally take two doses of Pertussin ES close together?

A: Regulatory documents advise against exceeding the maximum daily dose within a 24-hour period. Taking more than the recommended amount may lead to signs of overdose, such as increased sleepiness, dizziness, nausea, and vomiting. Adherence to the administration intervals detailed on the product label is required.

Q: Is the active substance in Pertussin ES a natural compound?

A: No. The active substance, Dextromethorphan, is officially classified as a synthetic compound. It is chemically manufactured and is derived from the morphinan chemical class of organic chemicals.

Q: Does Pertussin ES contain sugar or artificial sweeteners?

A: The official ingredients list found in the product labeling details all components. This list will confirm whether the oral solution formulation contains excipients used for flavoring or sweetening, such as sugar, artificial sweeteners (like sucralose), or sugar alcohols (like sorbitol).

Q: Why is it important to tell my doctor about all my non-prescription medicines before starting Pertussin ES?

A: It is important because Dextromethorphan can have serious interactions not just with prescription medications, but also with certain non-prescription drugs and supplements. These include specific herbal remedies and over-the-counter medications that might have additive serotonergic or CNS depressant effects.

Q: Is Pertussin ES considered a narcotic?

A: No. Pertussin ES (Dextromethorphan) is typically not classified as a controlled substance or narcotic under the US Controlled Substances Act. Although it is chemically related to opiates, official classification distinguishes it as a non-opioid cough suppressant.

Q: Are there specific genetic factors that affect how Pertussin ES works?

A: Yes, regulatory documents note that the rate at which the drug is broken down depends on an enzyme in the liver called CYP2D6. The activity of this enzyme is subject to genetic variation. Individuals classified as 'poor metabolizers' of this enzyme may experience a prolonged or exaggerated effect from the drug.

Storage and Disposal Requirements

Pertussin ES oral solution must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F). The product must be protected from freezing and should not be refrigerated. It is essential to keep the medicine in its original container, ensuring the cap is tightly closed to maintain stability and prevent moisture exposure.

To ensure safety, Pertussin ES must be stored out of the sight and reach of children.

Disposal of unused or expired medicine should utilize a drug take-back location as the preferred method, according to regulatory guidance. If a take-back option is unavailable, the medicine must be mixed with an undesirable substance, sealed in a container, and discarded in the household trash. The medication must not be flushed down the sink or toilet.